Natera/$NTRA
1D1W1MYTD1Y5YMAX
Capital at risk
About Natera
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
- Ticker
- $NTRA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 6,138
- Headquarters
- Austin, United States
- Website
- www.natera.com
Natera Metrics
BasicAdvanced
$53B
-
-$1.37
1.51
-
Price and volume
Market cap
$53B
Beta
1.51
52-week high
$369.69
52-week low
$157.43
Average daily volume
1.4M
Financial strength
Current ratio
2.999
Quick ratio
2.736
Long term debt to equity
0.079
Total debt to equity
0.131
Interest coverage (TTM)
-75.89%
Profitability
EBITDA (TTM)
-229.833
Gross margin (TTM)
65.23%
Net profit margin (TTM)
-7.11%
Operating margin (TTM)
-10.54%
Effective tax rate (TTM)
23.88%
Revenue per employee (TTM)
$440,000
Management effectiveness
Return on assets (TTM)
-8.08%
Return on equity (TTM)
-12.54%
Valuation
Price to revenue (TTM)
19.117
Price to book
29.12
Price to tangible book (TTM)
40.18
Price to free cash flow (TTM)
1,010.85
Free cash flow yield (TTM)
0.10%
Free cash flow per share (TTM)
0.365
Growth
Revenue change (TTM)
37.82%
Earnings per share change (TTM)
-28.65%
3-year revenue growth (CAGR)
42.73%
10-year revenue growth (CAGR)
29.03%
3-year earnings per share growth (CAGR)
-34.10%
10-year earnings per share growth (CAGR)
-0.78%
What the Analysts think about Natera
Analyst ratings (Buy, Hold, Sell) for Natera stock.
Analyst projections of the future price of Natera stock.
Bulls say / Bears say
Natera posted Q2 2026 revenue of $752.8 million, up 37.7% year-over-year, and raised its 2026 revenue guidance midpoint by $100 million to $2.85 billion–$2.91 billion, driven by processing over 1 million tests for the second consecutive quarter (Reuters).
Signatera™ received Class C IVDR certification in the European Union—the first personalized MRD test for solid tumors to achieve this—reducing regulatory hurdles for new clinical trials and ensuring continued EU patient access after the 2028 transition deadline (Reuters).
In June 2026, Signatera secured regulatory approval from Japan’s PMDA for use in colorectal cancer, making it the first PMDA-approved MRD test in Japan and broadening its addressable market in the region (Reuters).
Total operating expenses in Q2 2026 rose 21.5% year-over-year to $555.3 million—driven by headcount growth and increased clinical trial spending—which may erode margin expansion (Reuters).
Despite narrowing, Natera reported a net loss of $67 million in Q2 2026, highlighting that the company remains unprofitable as it scales its business (Reuters).
Management disclosed that early cancer detection initiatives incur over $100 million in annual operating costs with no current revenue, acting as a ‘boat anchor’ on near-term profitability and free cash flow (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 5 Sept 2026.
Natera Financial Performance
Revenues and expenses
Natera Earnings Performance
Company profitability
Upcoming events
No upcoming events
Natera News
AllArticlesVideos
Funds containing Natera
AllUSDEURGBP
Fund name | Fund size | $NTRA weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 2.02% |
iShares Healthcare Innovation€2B78 | €1.2B | 2.02% |
iShares Healthcare Innovation£DRDR | £1B | 2.02% |
iShares AI Adopters and Applications€AIAA | €169M | 1.01% |
iShares AI Adopters and Applications£AIAA | £145M | 1.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.